TrialBMC medicine2026

Evaluation and analysis of renal injury in patients with advanced renal cell carcinoma receiving first-line benmelstobart plus anlotinib: results from the ETER100 study.

Juan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.